Germline mutations in DNA repair genes can predict hereditary forms of cancer, particularly BRCA1/2 mutations in breast and ovarian cancers.13 Pathogenic somatic mutations in genes from the homologous recombination DNA repair pathway, such as BRCA1/2, ATM, RAD51C, and RAD51D, were implicated in chemosensitivity and prognosis of EOC patients.14,15 HGSC typically shows very high frequency of somatic TP53 mutations (~90%) and genomic heterogeneity.16 This evidence concerns the gene BRCA1 and ovarian carcinoma.